页 1 从 135 结果
BACKGROUND
Mycophenolate mofetil (MMF) is an immune suppressant that selectively inhibits activated lymphocytes. Its usefulness in treating psoriasis has not been systematically investigated.
OBJECTIVE
To evaluate efficacy and safety of MMF as a monotherapy for psoriasis.
METHODS
This is a
Alefacept belongs to the new generation of drugs applied in the treatment of psoriasis. It is an immunomodulatory recombinant, fully human lymphocyte function associated antigen-3/immunoglobulin G1 fusion protein (LFA-3-Ig) CD2 antagonist that targets memory-effector T cells by binding CD2 on the T
Many psoriasis patients are bothered by symptoms in highly visible, pruritic areas, such as the scalp.Evaluate efficacy and safety of apremilast for moderate to severe scalp psoriasis.This phase 3b, double-blind, The effect of oral doses of colchicine on pustule formation was studied in 32 patients with pustulosis palmaris et plantaris without associated psoriasis. Oral administration of colchicine, 1 to 2 mg daily, was started during periods of disease exacerbation, and the dosage was gradually decreased to
Mycophenolic acid (MPA), an inhibitor of purine synthesis, was evaluated for its therapeutic and adverse effects in 29 patients with psoriasis. MPA was administered orally for at least 12 weeks, during which time the daily dose was increased from 1600 to 4800 mg depending on occurrence of adverse
Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported.
OBJECTIVE
Treatment options for psoriasis offer trade-offs in terms of efficacy, convenience, and risk of adverse events. We evaluated patients' preferences with respect to benefit-risk in the treatment of psoriasis.
METHODS
A discrete choice experiment was conducted in adults from the UK with
OBJECTIVE
To evaluate the clinical effectiveness, safety, tolerability and cost-effectiveness of etanercept and efalizumab for the treatment of moderate to severe chronic plaque psoriasis.
METHODS
Major electronic databases and several Internet resources were searched up to April
BACKGROUND
Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production.
OBJECTIVE
Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.
METHODS
Phase II, 12-week,
5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous
I Employing psoralen plus solar irradiation therapy in 20 patients with plaque psoriasis, improvement was noted in 55% of the patients. The overall improvement rate was however higher (95%) with coal tar plus solar irradiation treatment in the other group of 20 patients. In both groups, improvement
Thirty-eight patients with plaque-type psoriasis were enrolled in a double-blind psoralen plus ultraviolet A (PUVA) treatment study comparing the efficacy and side effects of 5-methoxypsoralen (5-MOP) and 8-methoxypsoralen (8-MOP). Patients treated with 8-MOP healed significantly faster than those
OBJECTIVE
To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP).
METHODS
Open, randomized, controlled study.
METHODS
Phototherapy unit in a dermatology
BACKGROUND
Both bath psoralen plus ultraviolet A (PUVA) and oral PUVA with 8-methoxypsoralen (8-MOP) have been successfully used for the treatment of recalcitrant palmoplantar psoriasis. This trial was designed to assess the efficacy and side effects of the different treatment modalities in a
A clinical cooperative study involving 14 centers evaluated photochemotherapy (psoralen and high-intensity long-wave ultraviolet light [PUVA]) for psoriasis. Results from 465 patients treated with a PUVA-48 unit (equipped with 48 high-intensity UVA bulbs) and 110 patients treated with a PUVA-64 unit